A Phase 2, Single-Arm, Open-Label, Multicenter Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Trial Profile

A Phase 2, Single-Arm, Open-Label, Multicenter Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 May 2018

At a glance

  • Drugs Zanubrutinib (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Sponsors BeiGene
  • Most Recent Events

    • 09 May 2018 According to a BeiGene media release, the compay expects to present updated Phase I clinical data from this trial and pooled safety analysis in patients with hematologic malignancies at the 2018 European Hematology Association (EHA) Annual Congress (June 2018).
    • 09 May 2018 Status changed from recruiting to active, no longer recruiting, according to a BeiGene media release.
    • 08 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top